Aurinia Pharmaceuticals Announces Settlement with Teva over Generic Voclosporin

What Happened

• Aurinia Pharmaceuticals (and its subsidiary Aurinia Pharma U.S., Inc.) announced on August 19, 2026 that it has entered into a settlement agreement with Teva Pharmaceuticals Inc. to resolve patent infringement litigation brought by Aurinia in response to Teva’s filing of an Abbreviated New Drug Application (ANDA) seeking to market a generic 7.9 mg voclosporin oral capsule in the United States. The company furnished a press release (Exhibit 99.1) with the 8-K filing.

Key Details

• Filing date: Form 8-K furnished on August 19, 2026 (Exhibit 99.1 press release attached).
• Parties: Aurinia Pharmaceuticals Inc. and Aurinia Pharma U.S., Inc. (plaintiffs) and Teva Pharmaceuticals Inc. (defendant/ANDA filer).
• Subject: Settlement to resolve patent infringement litigation related to Teva’s ANDA for 7.9 mg voclosporin oral capsules.
• Terms: The 8-K and attached press release do not disclose monetary or specific commercial terms; the filing states the information is being furnished (not “filed”) and does not admit materiality.

Why It Matters

• This settlement directly addresses Teva’s attempt to market a generic version of voclosporin, Aurinia’s product, which could affect future competition for the drug in the U.S. market.
• Because the filing provides no financial or timing details about the settlement, investors should note the litigation is described as resolved but should look for follow-up disclosures or company updates for any impact on revenue, exclusivity, or legal obligations. The press release is attached to the 8-K for further context.